Monday 19th October 2020 |
Text too small? |
• Second phase of national clinical trial in Sichuan Province reported outstanding results
• Conducted by China Obstetrics and Gynaecology Association (COGA) a peak gynaecology body in China.
• Trial conducted across 14 hospitals with 1,243 patients participating
• Both sensitivity and specificity targeting pre-cancerous and cancerous cervical cells performed in aggregate better than other screening methods (see below table)
Truscreen Group Limited (NZX: TRU ) (Truscreen or Company) is pleased to advise results from The China Obstetrics and Gynaecology Association (COGA) ongoing national clinical trial that will screen over 20,000 women in 100 top-tier public hospitals across 10 provinces in China. The COGA evaluation compares the TruScreen technology to Liquid Based Cytology (LBC), and HPV DNA testing (HPV) and targets a nationwide consensus on Truscreen technology application in China as the main outcome of this large-scale trial.
See the link below for more details:
Sichuan Province Trial Confirms Truscreen Technology
Source: Truscreen Group Limited
No comments yet
KMD - 1H FY2024 Interim Results
SCT - Resignation of Chief Executive Officer
March 19th Morning Report
SKC - APPOINTMENT OF CHIEF INFORMATION OFFICER
NWF - Chief Executive Officer Warren Koia Resignation
March 18th Morning Report
Pacific Edge Directors Give Notice of Retirement
Meridian Energy monthly operating report for February 2024
Another unworkable farming rule bites the dust
March 14th Morning Report